GlobeNewsWire
10 Jun 2026, 00:22 UTC · 9h ago
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
10 Jun 2026, 00:22 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Parabilis Medicines priced an upsized IPO of 33.5 million shares at $20.00 per share, expecting $670 million in gross proceeds. — A successful, upsized IPO provides substantial capital for a clinical-stage biotech and signals strong institutional demand.
+0.60Regeneron Pharmaceuticals, Inc. entered into a concurrent private placement to purchase 4,166,666 shares at $18.00 per share. — Direct investment from an industry leader like Regeneron serves as a strong strategic validation of the company's technology.
+0.50Parabilis common stock is expected to begin trading on the Nasdaq Global Select Market on June 10, 2026, under the ticker 'PBLS'. — This is a standard procedural step for the IPO and provides the mechanism for price discovery.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company successfully priced an upsized initial public offering expected to raise approximately $670 million.
The company is making a strategic investment in Parabilis Medicines through a concurrent private placement.
BofA Securities is acting as an active book-running manager for the IPO.
Evercore is acting as an active book-running manager for the IPO.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
4h ago
